A detailed history of Cornerstone Planning Group LLC transactions in Biogen Inc. stock. As of the latest transaction made, Cornerstone Planning Group LLC holds 28 shares of BIIB stock, worth $4,866. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28
Previous 16 75.0%
Holding current value
$4,866
Previous $3.48 Million 59.58%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$190.52 - $236.72 $2,286 - $2,840
12 Added 75.0%
28 $5.56 Million
Q1 2024

May 07, 2024

SELL
$212.02 - $267.71 $12,297 - $15,527
-58 Reduced 78.38%
16 $3.48 Million
Q4 2023

Feb 12, 2024

BUY
$222.59 - $267.94 $4,229 - $5,090
19 Added 34.55%
74 $19.1 Million
Q3 2023

Nov 08, 2023

SELL
$253.3 - $285.89 $506 - $571
-2 Reduced 3.51%
55 $14.1 Million
Q2 2023

Aug 15, 2023

BUY
$275.25 - $318.06 $10,459 - $12,086
38 Added 200.0%
57 $16.2 Million
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $4,796 - $5,827
19 New
19 $5.32 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Cornerstone Planning Group LLC Portfolio

Follow Cornerstone Planning Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornerstone Planning Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cornerstone Planning Group LLC with notifications on news.